The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

That brings the total to 25 drugs that will have lower price tags under a historic new program that allows the government to ...

Under the law, more drugs will be added to the negotiation process in coming years. Ozempic and Wegovy are made by Novo ...

The firm said in a note Wednesday that despite Novo Nordisk's challenges with supply issues for its obesity drug Wegovy, the company anticipates an improvement in prescription levels in the coming ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss ... makes the main active ingredient in its popular obesity and diabetes injections Wegovy and Ozempic in Denmark, and exports it to the United ...

(see more details here). Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical firm that is one of the players in the global weight loss drug industry. Its Wegovy weight loss drug has enabled the ...

Danish multinational pharmaceutical giant Novo Nordisk is the sole owner of semaglutide, the active ingredient in both Ozempic and Wegovy. A month’s supply of Ozempic is close to $1,000 without ...